Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Cyramza ® (ramucirumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Cyramza® (ramucirumab): Use with COVID-19 Vaccines
The use of vaccines against SARS-CoV-2 in patients treated with ramucirumab has not been studied.
Administration of COVID-19 Vaccines to Patients Receiving Ramucirumab
The use of vaccines against SARS-CoV-2 in patients treated with ramucirumab has not been studied.
Severe acute respiratory syndrome coronavirus 2 is an emerging virus that has caused the recent COVID-19 pandemic. There are several vaccines against SARS-CoV-2 currently available, and others are under development.1,2
SARS-CoV-2 Vaccination With Ramucirumab
The use of a SARS-CoV-2 vaccine in patients treated with Cyramza (ramucirumab) has not been studied by Lilly.
Decisions regarding the use of any vaccination, including SARS-CoV-2 vaccines, in patients treated with Cyramza should be made at the discretion of the prescribing physician using their best clinical judgment, and must be made by the clinician after careful consideration of risk factors of the patient as well as the risks and benefits of vaccination. Consultation with an infectious disease expert may be helpful in high-risk or emergency situations such as the current COVID-19 pandemic.
Infectious Disease Resources for COVID-19 Vaccines
For the most up-to-date information regarding each vaccine in development, please check the World Health Organization and Centers for Disease Control information at
https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
and
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html.
Additional information and considerations for the use of a SARS-CoV-2 vaccine in patients being treated for cancer is available from ESMO at: https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination.
References
1Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237. https://doi.org/10.1038/s41392-020-00352-y
2Jackson LA, Anderson EJ, Rouphael NG, et al; mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020;383(20):1920-1931. https://doi.org/10.1056/NEJMoa2022483
Glossary
COVID-19 = coronavirus disease 2019
Lilly = Eli Lilly and Company
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
Date of Last Review: 05 January 2021